FDA approves Zytiga for late-stage prostate cancer

Posted by Food and Drug Administration--Press Releases on Thursday Apr 28, 2011 Under News

The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).

Be Sociable, Share!

Comments are closed.